Lévis-Saint-Nom (FR)
{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~20 mi. (Saint-Cloud, France, +192 more cities)
facility
Institut Curie
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~20 mi. (Saint-Cloud, France, +207 more cities)
facility
Institut Curie - Centre Rene Huguenin ( Site 0917)
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~20 mi. (Saint-Cloud, France, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
condition
Breast Carcinoma
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
city
~20 mi. (Saint-Cloud, France, +15 more cities)
facility
Novartis Investigative Site
biomarker
ERBB2 Amplification, +2 more biomarkers
condition
Breast Carcinoma
drug
alpelisib, +2 more drugs
drug type
targeted therapy
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~22 mi. (Suresnes, France, +226 more cities)
facility
Hopital Foch ( Site 0428)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~22 mi. (Suresnes, France, +130 more cities)
facility
Hôpital Foch-Urology department ( Site 1351)
condition
Bladder Urothelial Carcinoma
drug
BCG solution, +1 more drug
drug type
immunotherapy
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~22 mi. (Suresnes, France, +159 more cities)
facility
Hopital Foch ( Site 0483)
condition
Superficial Bladder Urothelial Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~22 mi. (Suresnes, France, +127 more cities)
facility
Hopital Foch ( Site 1905)
condition
Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
city
~22 mi. (Suresnes, France, +67 more cities)
facility
Hôpital Foch ( Site 1019)
condition
Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition
drug
carboplatin, +5 more drugs
drug type
chemotherapy, +1 more type